|
Patient identifier and weight were unavailable from the attached journal article or by the authors.Patient age and patient sex not made available the attached journal article or by the authors.The article reports that the mean patient age was 65 years old and the consisted of male patients in the study.Therefore 65 and male were used.Event date is approximated.Date provided is when the journal article was accepted.Citation: natarajan s, jones t, priester a et al: focal laser ablation of prostate cancer: feasibility of magnetic resonance imaging/ultrasound fusion for guidance.Juro14679_proof 2017; 198: 1-9.Http://dx.Doi.Org/10.1016/j.Juro.2017.04.017.The exact system information could not be determined as it was not provided.However, the system listed on this form was at the address listed in the article during the time some of the surgeries were completed.Device udi not provided as actual product used for this study is unknown.Device manufacturing date is dependent on lot number/serial number, therefore, unavailable.Followup attempt has been made to obtain additional information.No further information provided in the journal article or from the authors.The author could not provide any additional information or insight as he was not at the site when the surgeries were performed.No request for service have been received from the customer regarding these events.No parts have been replaced or returned to the manufacturer for evaluation.Medtronic navigation is filing this mdr to ensure visibility to a patient event as a result of a procedure that utilized medtronic navigation's thermal therapy system.There is no allegation to suggest that medtronic navigation's device caused or contributed to the reported event.
|
|
The attached journal article was forwarded by medtronic representative.Article indicated the use of thermal therapy system.Focal laser ablation is a potential treatment in some men with prostate cancer.Currently focal laser ablation is performed by radiologists in a magnetic resonance imaging unit (in bore).We evaluated the safety and feasibility of performing focal laser ablation in a urology clinic (out of bore) using magnetic resonance imaging-ultrasound fusion for guidance.A total of 11 men with intermediate risk prostate cancer were enrolled in this prospective, institutional review board approved pilot study.Magnetic resonance imaging-ultrasound fusion was used to guide laser fibers transrectally into regions of interest harboring intermediate risk prostate cancer.Thermal probes were inserted for real-time monitoring of intraprostatic temperatures during laser activation.Multiparametric magnetic resonance imaging (3 tesla) was done immediately after treatment and at 6 months along with comprehensive fusion biopsy.Ten of 11 patients were successfully treated while under local anesthesia.Mean procedure time was 95 minutes (range 71 to 105).Posttreatment magnetic resonance imaging revealed a confined zone of nonperfusion in all 10 men.Mean zone volume was 4.3 cc (range 2.1 to 6.0).No ctcae grade 3 or greater adverse events developed and no changes were observed in urinary or sexual function.At 6 months magnetic resonance imaging-ultrasound fusion biopsy of the treatment site showed no cancer in 3 patients, microfocal gleason 3 þ 3 in another 3 and persistent intermediate risk prostate cancer in 4.Reported event: a 38 grade 1 adverse events during a 6-month period.A 6 grade 2 adverse events during a 6-month period.Hematuria was the most frequent adverse event following treatment, which resolved in a few days in all patients without intervention.No treatment related serious adverse events (ctcae grade 3 or greater) were noted.
|